Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.91
LGND's Cash to Debt is ranked lower than
81% of the 858 Companies
in the Global Biotechnology industry.

( Industry Median: 68.31 vs. LGND: 0.91 )
Ranked among companies with meaningful Cash to Debt only.
LGND' s 10-Year Cash to Debt Range
Min: 0.14  Med: 0.47 Max: No Debt
Current: 0.91
Equity to Asset 0.23
LGND's Equity to Asset is ranked lower than
87% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. LGND: 0.23 )
Ranked among companies with meaningful Equity to Asset only.
LGND' s 10-Year Equity to Asset Range
Min: -0.83  Med: 0.12 Max: 0.68
Current: 0.23
-0.83
0.68
F-Score: 7
Z-Score: 2.62
M-Score: -3.31
WACC vs ROIC
2.32%
34.51%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 29.42
LGND's Operating margin (%) is ranked higher than
91% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -71.95 vs. LGND: 29.42 )
Ranked among companies with meaningful Operating margin (%) only.
LGND' s 10-Year Operating margin (%) Range
Min: -466.69  Med: -44.94 Max: 30.51
Current: 29.42
-466.69
30.51
Net-margin (%) 46.00
LGND's Net-margin (%) is ranked higher than
95% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -68.66 vs. LGND: 46.00 )
Ranked among companies with meaningful Net-margin (%) only.
LGND' s 10-Year Net-margin (%) Range
Min: -666.1  Med: -30.67 Max: 2184.64
Current: 46
-666.1
2184.64
ROE (%) 68.29
LGND's ROE (%) is ranked higher than
98% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. LGND: 68.29 )
Ranked among companies with meaningful ROE (%) only.
LGND' s 10-Year ROE (%) Range
Min: -1046.55  Med: -119.17 Max: 997.71
Current: 68.29
-1046.55
997.71
ROA (%) 13.63
LGND's ROA (%) is ranked higher than
92% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: -26.75 vs. LGND: 13.63 )
Ranked among companies with meaningful ROA (%) only.
LGND' s 10-Year ROA (%) Range
Min: -95.66  Med: -12.71 Max: 112.83
Current: 13.63
-95.66
112.83
ROC (Joel Greenblatt) (%) 4174.93
LGND's ROC (Joel Greenblatt) (%) is ranked higher than
100% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: -365.20 vs. LGND: 4174.93 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
LGND' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1252.88  Med: -138.16 Max: 2901.11
Current: 4174.93
-1252.88
2901.11
Revenue Growth (3Y)(%) 25.60
LGND's Revenue Growth (3Y)(%) is ranked higher than
81% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. LGND: 25.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
LGND' s 10-Year Revenue Growth (3Y)(%) Range
Min: -61  Med: -4.00 Max: 43.1
Current: 25.6
-61
43.1
EBITDA Growth (3Y)(%) 105.40
LGND's EBITDA Growth (3Y)(%) is ranked higher than
98% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: -4.40 vs. LGND: 105.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
LGND' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -68.6  Med: -1.10 Max: 196.7
Current: 105.4
-68.6
196.7
EPS Growth (3Y)(%) 2.50
LGND's EPS Growth (3Y)(%) is ranked higher than
60% of the 420 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. LGND: 2.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
LGND' s 10-Year EPS Growth (3Y)(%) Range
Min: -63.8  Med: -17.10 Max: 50.1
Current: 2.5
-63.8
50.1
» LGND's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

LGND Guru Trades in Q3 2014

Paul Tudor Jones 5,200 sh (New)
Joel Greenblatt 552,053 sh (+894.83%)
RS Investment Management 1,493,635 sh (+7.29%)
Jim Simons Sold Out
Ken Fisher 35,258 sh (-4.47%)
» More
Q4 2014

LGND Guru Trades in Q4 2014

Ken Fisher 81,908 sh (+132.31%)
RS Investment Management 1,430,650 sh (unchged)
Paul Tudor Jones Sold Out
RS Investment Management 1,430,650 sh (-4.22%)
Joel Greenblatt 3,766 sh (-99.32%)
» More
Q1 2015

LGND Guru Trades in Q1 2015

Ken Fisher 81,908 sh (unchged)
Joel Greenblatt Sold Out
RS Investment Management 1,187,500 sh (-17.00%)
» More
Q2 2015

LGND Guru Trades in Q2 2015

Jim Simons 96,094 sh (New)
Ken Fisher 80,608 sh (-1.59%)
RS Investment Management 982,960 sh (-17.22%)
RS Investment Management 982,960 sh (-17.22%)
» More
» Details

Insider Trades

Latest Guru Trades with LGND

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 61.22
LGND's P/E(ttm) is ranked lower than
66% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 36.10 vs. LGND: 61.22 )
Ranked among companies with meaningful P/E(ttm) only.
LGND' s 10-Year P/E(ttm) Range
Min: 0.99  Med: 99.90 Max: 269.4
Current: 61.22
0.99
269.4
Forward P/E 30.86
LGND's Forward P/E is ranked lower than
62% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 22.73 vs. LGND: 30.86 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 54.60
LGND's PE(NRI) is ranked lower than
67% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 35.00 vs. LGND: 54.60 )
Ranked among companies with meaningful PE(NRI) only.
LGND' s 10-Year PE(NRI) Range
Min: 23.18  Med: 136.04 Max: 99999999.99
Current: 54.6
23.18
99999999.99
P/B 29.19
LGND's P/B is ranked lower than
95% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. LGND: 29.19 )
Ranked among companies with meaningful P/B only.
LGND' s 10-Year P/B Range
Min: 11.11  Med: 22.51 Max: 182
Current: 29.19
11.11
182
P/S 28.09
LGND's P/S is ranked lower than
70% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.19 vs. LGND: 28.09 )
Ranked among companies with meaningful P/S only.
LGND' s 10-Year P/S Range
Min: 3.13  Med: 12.82 Max: 754
Current: 28.09
3.13
754
PFCF 145.97
LGND's PFCF is ranked lower than
80% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 39.55 vs. LGND: 145.97 )
Ranked among companies with meaningful PFCF only.
LGND' s 10-Year PFCF Range
Min: 33.11  Med: 87.13 Max: 479.5
Current: 145.97
33.11
479.5
POCF 63.27
LGND's POCF is ranked lower than
71% of the 202 Companies
in the Global Biotechnology industry.

( Industry Median: 32.56 vs. LGND: 63.27 )
Ranked among companies with meaningful POCF only.
LGND' s 10-Year POCF Range
Min: 20.29  Med: 66.77 Max: 249.25
Current: 63.27
20.29
249.25
Shiller P/E 226.94
LGND's Shiller P/E is ranked lower than
85% of the 113 Companies
in the Global Biotechnology industry.

( Industry Median: 44.53 vs. LGND: 226.94 )
Ranked among companies with meaningful Shiller P/E only.
LGND' s 10-Year Shiller P/E Range
Min: 3.2  Med: 11.09 Max: 407.95
Current: 226.94
3.2
407.95
Current Ratio 10.96
LGND's Current Ratio is ranked higher than
78% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. LGND: 10.96 )
Ranked among companies with meaningful Current Ratio only.
LGND' s 10-Year Current Ratio Range
Min: 0.28  Med: 1.72 Max: 10.96
Current: 10.96
0.28
10.96
Quick Ratio 10.92
LGND's Quick Ratio is ranked higher than
78% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.01 vs. LGND: 10.92 )
Ranked among companies with meaningful Quick Ratio only.
LGND' s 10-Year Quick Ratio Range
Min: 0.26  Med: 1.61 Max: 10.92
Current: 10.92
0.26
10.92
Days Inventory 46.00
LGND's Days Inventory is ranked higher than
80% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: 120.98 vs. LGND: 46.00 )
Ranked among companies with meaningful Days Inventory only.
LGND' s 10-Year Days Inventory Range
Min: 33.18  Med: 98.35 Max: 1280.32
Current: 46
33.18
1280.32
Days Sales Outstanding 28.44
LGND's Days Sales Outstanding is ranked higher than
79% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. LGND: 28.44 )
Ranked among companies with meaningful Days Sales Outstanding only.
LGND' s 10-Year Days Sales Outstanding Range
Min: 5.79  Med: 45.99 Max: 146.43
Current: 28.44
5.79
146.43

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 38.35
LGND's Price/Projected FCF is ranked lower than
91% of the 158 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. LGND: 38.35 )
Ranked among companies with meaningful Price/Projected FCF only.
LGND' s 10-Year Price/Projected FCF Range
Min: 42.57  Med: 70.72 Max: 98.86
Current: 38.35
42.57
98.86
Price/Median PS Value 2.10
LGND's Price/Median PS Value is ranked lower than
78% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: 1.08 vs. LGND: 2.10 )
Ranked among companies with meaningful Price/Median PS Value only.
LGND' s 10-Year Price/Median PS Value Range
Min: 0.28  Med: 0.91 Max: 52.59
Current: 2.1
0.28
52.59
Earnings Yield (Greenblatt) (%) -58.75
LGND's Earnings Yield (Greenblatt) (%) is ranked lower than
92% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. LGND: -58.75 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
LGND' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -66.92  Med: 1.10 Max: 1.9
Current: -58.75
-66.92
1.9

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 82 117 150
EPS($) 2.22 2.94 4.38
EPS without NRI($) 2.22 2.94 4.38

Business Description

Industry: Biotechnology » Biotechnology
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:LGDN.Germany,
Ligand Pharmaceuticals Inc was incorporated in Delaware in 1987. It is a biopharmaceutical company engaged in developing or acquiring royalty revenue generating assets and coupling them to a lean corporate cost structure. The Company has evaluated ASC 280 and has identified two reportable segments: the development and commercialization of drugs using Captisol technology by CyDex Pharmaceuticals, Inc. and the biopharmaceutical company. With its portfolio of assets across numerous technology types, therapeutic areas, drug targets, and industry partners, the Company offers investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. It has multiple partnered programs in its portfolio that are either in or nearing the regulatory approval process. GSKs Promacta (Eltrombopag) is the first oral thrombopoietin (TPO) receptor agonist therapy for the treatment of adult patients with chronic immune (idiopathic) thrombocytopenic purpura, or ITP. The Company currently receives royalty revenues from Pfizer, Inc., or Pfizer, for sales of the pain therapeutic Avinza. The drug is also marketed in Spain under the brand name Conbriza through a co-promotion with Almirall, an international pharmaceutical company based in Spain. The Company currently has no manufacturing facilities. It currently outsource the production of Captisol to Hovione FarmaCiencia SA, or Hovione, a supplier of active pharmaceutical ingredients, or APIs and API intermediates located in Portugal. Its competitive position also depends upon its ability to attract and retain qualified personnel, obtain patent protection or otherwise develop proprietary products or processes, and secure sufficient capital resources for the often substantial period between technological conception and commercial sales. The Company is subject to rigorous regulation by federal and various state authorities, including the FDA.
» More Articles for LGND

Headlines

Articles On GuruFocus.com
Dan Loeb Sees Opportunity in Latest Activist Target Baxter International Aug 06 2015 
Dan Loeb Sees Opportunity in Latest Activist Target Baxter International Aug 06 2015 
dick Feb 13 2015 
Ligand Pharmaceuticals - Severe competitive threat to key royalty program and “going concern” ri Jun 19 2014 
5 Hot Stocks to Consider Now Mar 30 2012 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) May 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2009 
Ligand to Acquire Neurogen for Stock and Contingent Value Rights Aug 24 2009 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 04 2009 

More From Other Websites
Novartis' (NVS) Promacta Label Further Expanded in U.S. Aug 26 2015
Ligand Pharmaceuticals, Inc. Earnings Q2, 2015 Aug 26 2015
FDA Expands Use of Promacta® to Include Treatment of Children Ages 1 and Older with Chronic Immune... Aug 24 2015
FDA Expands Use of Promacta® to Include Treatment of Children Ages 1 and Older with Chronic Immune... Aug 24 2015
LIGAND PHARMACEUTICALS INC Financials Aug 12 2015
10-Q for Ligand Pharmaceuticals, Inc. Aug 08 2015
Dan Loeb Sees Opportunity in Latest Activist Target Baxter International Aug 06 2015
LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Aug 06 2015
SurModics (SRDX) Beats on Q3 Earnings, Improves Outlook - Analyst Blog Aug 06 2015
Poseida Therapeutics, Inc., Expands Board of Directors Aug 05 2015
Ligand Pharmaceuticals Beats on Q2 Earnings, Affirms View - Analyst Blog Aug 05 2015
LIGAND PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 05 2015
Ligand Reports Second Quarter 2015 Financial Results Aug 05 2015
Matthew Korenberg to Join Ligand Pharmaceuticals as Chief Financial Officer Aug 05 2015
Edited Transcript of LGND earnings conference call or presentation 4-Aug-15 8:30pm GMT Aug 04 2015
Ligand posts 2Q profit Aug 04 2015
Ligand posts 2Q profit Aug 04 2015
LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 04 2015
Matthew Korenberg to Join Ligand Pharmaceuticals as Chief Financial Officer Aug 04 2015
Ligand Reports Second Quarter 2015 Financial Results Aug 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK